Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study

References

• Chanda ML, Alvin MD, Schnitzer TJ, Apkarian AV. Pain characteristic differences between subacute and chronic back pain. J Pain 2011;12:792-800
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Health, United States, 2006. With Chartbook on Trends in the Health of Americans. DHS Publication No 2006-1232. Hyattsville, MD: National Center for Health Statistics, 2006. Available at: http://www.cdc.gov/nchs/data/hus/hus06.pdf [Last accessed 1 February 2014]
   Google Scholar
• United States Census Bureau – Population estimates. 2010. Available at: http://www.census.gov/popest/research/eval-estimates/eval-est2010.html [Last accessed 1 February 2014]
   Google Scholar
• Johnson M, Collett B, Castro-Lopes JM. The challenges of pain management in primary care: a pan-European survey. J Pain Res 2013;6:393-401
   PubMed Web of Science ®Google Scholar
• WHO. Normative Guidelines on Pain Management. Report of a Delphi Study to determine the need for guidelines and to identify the number and topics of guidelines that should be developed by WHO. 2007. Available at: http://www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines.pdf [Last accessed 1 February 2014]
   Google Scholar
• British Pain Society. Opioids for persistent pain: good practice. January 2010. Available at: http://www.britishpainsociety.org [Last accessed 10 April 2014]
   Google Scholar
• American Pain Society, American Academy of Pain Medicine. Guideline for the use of chronic opioid therapy in chronic noncancer pain. Evidence review. 2009. Available at: http://www.americanpainsociety.org [Last accessed 10 April 2014]
   Google Scholar
• Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8:181-6
   PubMedGoogle Scholar
• Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2 – guidance. Pain Physician 2012;15:S67-116
   PubMed Web of Science ®Google Scholar
• Barnett M. Alternative opioids to morphine in palliative care: a review of current practice and evidence. Postgrad Med J 2001;77:371-8
   PubMed Web of Science ®Google Scholar
• Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001;9:84-96
   PubMed Web of Science ®Google Scholar
• Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29(5 Suppl):S57-66
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
   PubMedGoogle Scholar
• Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2009:CD003447
   Google Scholar
• Coluzzi F, Mattia C. OROS hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol 2010;76:1072-84
   PubMed Web of Science ®Google Scholar
• Patwekar SL, Baramade MK. Controlled release approach to novel multiparticulate drug delivery system. Int J Pharm Pharm Sci 2012;4:757-63
   Google Scholar
• Reddy S, Palash D, Das H, Ghosh A. MUPS (multiple unit pellet system) tablets – a brief review. J Pharm Biomed Sci 2011;12:1-5
   Google Scholar
• Hydromorphon-Präparat mit 24-Stunden-Wirksamkeit. Neuartige Multiple-Unit-Pellet-Formulierung unterstützt einfaches Therapieschema. Der Schmerz 2015;29
   Google Scholar
• Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79:1428-37
   PubMed Web of Science ®Google Scholar
• Grosset AB, Roberts MS, Woodson ME, et al. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. J Pain Symptom Manage 2005;29:584-94
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;16:3222-9
   PubMed Web of Science ®Google Scholar
• Finn JW, Walsh TD, MacDonald N, et al. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 1993;11:967-72
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Bingham CO 3rd, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507
   PubMed Web of Science ®Google Scholar
• Fardellone P, Zaim M, Saurel AS, Maheu E. Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol J 2013;7:1-12
   PubMedGoogle Scholar
• Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012;153:1148-58
   PubMed Web of Science ®Google Scholar
• Jensen MP. The Validity and Reliability of Pain Measures for use in Clinical Trials in Adults: Review Paper Written for the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) meeting, 12–13 April 2003. Available at: http://www.immpact.org/static/meetings/Immpact2/background/Jensen_review.pdf [Last accessed 1 February 2014]
   Google Scholar
• Jensen MP. Increasing the reliability, validity, and responsiveness of pain intensity ratings. 2010. Available at: http://www.immpact.org/meetings/Immpact13/background13.html [Last accessed 1 February 2014]
   Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36
   PubMed Web of Science ®Google Scholar
• Carson S, Thakurta S, Low A, et al. Drug Class Review: Long-Acting Opioid Analgesics: Final Update 6 Report. Portland (OR): Oregon Health & Science University, July 2011
   Google Scholar
• Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother 2006;40:1327-35
   PubMed Web of Science ®Google Scholar
• Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;26:1026-48
   PubMed Web of Science ®Google Scholar
• Lux EA, Janecki M, Maritz MA. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet. Curr Med Res Opin 2014;30: 2365-75
   PubMed Web of Science ®Google Scholar
• Junker U, Wirz S. Review article: chronobiology: influence of circadian rhythms on the therapy of severe pain. J Oncol Pharm Pract 2010;16:81-7
   PubMedGoogle Scholar
• Bellamy N, Sothern RB, Campbell J, Buchanan WW. Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. Ann Rheum Dis 2002;61:1075-80
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007;56:399-408
   PubMed Web of Science ®Google Scholar
• Hagen NA, Thirlwell M, Eisenhoffer J, et al. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. J Pain Symptom Manage 2005;29:80-90
   PubMed Web of Science ®Google Scholar
• Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc 2009;84:602-12
   PubMed Web of Science ®Google Scholar
• Pedersen L, Borchgrevink PC, Riphagen II, Fredheim OM. Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review. Acta Anaesthesiol Scand 2014;58:390-401
   PubMed Web of Science ®Google Scholar
• Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15:179-83
   PubMed Web of Science ®Google Scholar
• Balch RJ, Trescot A. Extended-release morphine sulfate in treatment of severe acute and chronic pain. J Pain Res 2010;3:191-200
   PubMedGoogle Scholar
• Kerr RO, Tester WJ. A patient preference study comparing two extended-release morphine sulfate formulations (once daily Kadian versus twice daily MS Contin) for cancer pain. Clin Drug Invest 2000;19:25-32
   Web of Science ®Google Scholar